Joshua Pinto, Ph.D.

Joshua Pinto, Ph.D.

PresidentatNeumora Therapeutics· In proxies 2024–2025

Pay in FY2025+46% from the year before · Neumora Therapeutics stock -83.1% the same year

Joshua Pinto, Ph.D. was paid $6.7M in FY2025 (Dec), up 46%. Neumora Therapeutics stock fell 83.1% that year.

Pay$100 in the stock at the end of FY23 → $10
Pay is from the Summary Compensation Table of each Neumora Therapeutics proxy. The stock line is the value of $100 put in the stock at the start, from the price change of each fiscal year. Dividends are not in it.

Experience

  1. Neumora TherapeuticsPublic company · 2 yr
    • President2024 – Present · 2 yrStock in role -98%

Roles come from the proxy statements of each company.

Activity

For the press:Download CSVDownload PNGHow to use our data

Two people shown as one, or a wrong number?